TITLE

OTC Claritin prompts coverage decisions

AUTHOR(S)
Elswick, Jill
PUB. DATE
February 2003
SOURCE
Employee Benefit News;Feb2003, Vol. 17 Issue 2, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Focuses on the strategies that plan sponsors may adopt to cover Claritin, a non-sedating antihistamine over the counter drug manufactured by Schering-Plough. Price of Claritin; Advantage of covering Claritin; Drawback of covering Claritin.
ACCESSION #
9036920

 

Related Articles

  • Allergy Drugs: There Are Some Differences. Napoli, Maryann // HealthFacts;Jun2001, Vol. 26 Issue 6, p6 

    Argues that Claritin, an allergy medication from Schering-Plough Corp., is no more effective than other antihistamines.

  • Claritin gets OK for treatment of chronic hives. Rodgers, Katie // Drug Topics;11/6/95, Vol. 139 Issue 21, p44 

    Reports on the indication of Claritin (loratadine), a nonsedating antihistamine from Schering-Plough Corp. Fact of life for unfortunate sufferers of chronic urticaria know as hives; Require of long-term antihistamine therapy to reduce the number of exacerbations; Advantages of loratadine over...

  • Claritin Hits Store Shelves. Branch Jr., Al // Pharmaceutical Executive;Jan2003, Vol. 23 Issue 1, p24 

    Reports on the Schering-Plough's over-the-counter sale of its antihistamine, Claritin. Impact of the product release on the pharmaceutical industry; Reason for the projected decline in revenue from the antihistamine product; Retail prices of the Claritin.

  • Non-drowsy antihistamine syrup for children.  // Modern Medicine;Dec96, Vol. 64 Issue 12, p29 

    Reports that a syrup form of loratadine (Claritin) manufactured by Schering-Plough has been approved by the US Food and Drug Administration. Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis and treatment of chronic urticaria in children.

  • Phase III Trials Under Way For Claritin Metabolite. Kim, Ellen // Drug Store News;10/19/98, Vol. 20 Issue 17, pCP16 

    Reports on Schering-Plough Corp.'s initiation of its phase III trials for desloratadine, an active metabolite of the antihistamine Claritin. Terms of the company's licensing agreement with Sepracor.

  • Antihistamine drug wars: Claritin vs. Zyrtec.  // HealthFacts;Jun96, Vol. 21 Issue 205, p2 

    Reports on the dispute between Schering-Plough, maker of the antihistamine Claritin, and Pfizer, maker of the antihistamine Zyrtec. Out-of-court settlement of lawsuits; Schering-Plough's claim that Pfizer marketed Zyrtec as non-sedating when it did not meet federal standards; Schering-Plough's...

  • Patient Care OTC Antihistamine Eye Drop.  // Review of Optometry;9/15/2009 Part 1 of 2, Vol. 146 Issue 9, p116 

    The article evaluates the Claritin Eye, an antihistamine eye drop, from Schering-Plough Corp.

  • DTC catapults Schering to top rank of growth companies. Seiden, Carl // Medical Marketing & Media;Dec99, Vol. 34 Issue 12, p82 

    Features United States pharmaceutical industry leader Schering-Plough Corp. Success of Schering's non-sedating antihistamine product Claritin; Financial performance for 1999; Strategy for promoting a hepatitis product; Lack of potential blockbusters in the long-term.

  • NEW LAUNCH.  // Drug Topics;7/07/2003, Vol. 147 Issue 13, p87 

    Reports on Schering-Plough's launched of Clarinex 5 milligrams RediTabs, an orally disintegrating table formulation of the prescription nonsedating antihistamine desloratadine. Use of the drug for treatment of allergy symptoms.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics